Veracyte, Inc. (VCYT)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 14, 2025

$41.11

P/E Ratio

N/A

Market Cap

$3.19B

Description
Add to research

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Metrics
Add to research

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryMedical Specialties
  • TickerVCYT
  • Price$41.11+3.84%

Trading Information

  • Market cap$3.19B
  • Float98.76%
  • Average Daily Volume (1m)724,473
  • Average Daily Volume (3m)758,853
  • EPS-$0.14

Company

  • Revenue$425.33M
  • Rev growth (1yr)28.58%
  • Net income$15.16M
  • Gross margin66.19%
  • EBITDA margin15.61%
  • EBITDA$18.08M
  • EV$2.42B
  • EV/Revenue5.68
  • P/EN/A
  • P/S7.58
  • P/B2.71
  • Debt/Equity1.67
Documents
Add to research